SAN DIEGO—Aethlon Medical, Inc. recently announced that it has demonstrated the ability to capture immunosuppressive exosomes derived from individuals with lymphoma and colorectal cancer.
In the lymphoma study, conducted at the City of Hope Cancer Research Hospital in California, exosomes derived from lymphoma patients were circulated through Aethlon Medical's Hemopurifier. Each sample confirmed significant exosome capture rate validating that the company's Hemopurifier® is a candidate therapy to address lymphoma.
In a separate study, exosomes derived from colorectal cancer patients were also circulated through the company's Hemopurifier. The results for the colorectal study also confirmed significant exosome capture rate and the prospect of applying the Hemopurifier® as a therapeutic for this type of cancer. The company anticipates providing additional details of these studies in a forthcoming report.
Additionally, as previously announced, Exosome Sciences, Inc., a wholly owned subsidiary of Aethlon Medical, is developing its proprietary ELLSA assay that will allow researchers to detect exosomes in blood and other fluids. These studies further validate the company's detection assay in identifying lymphoma and colorectal cancer derived from cancer-released exosomes. As a result, this diagnostic tool offers the potential to improve lymphoma and colorectal cancer diagnosis and monitor disease progression.
